Elanco Animal Health (NYSE:ELAN) Coverage Initiated at KeyCorp

Equities research analysts at KeyCorp started coverage on shares of Elanco Animal Health (NYSE:ELAN) in a note issued to investors on Friday,Benzinga reports. The firm set an “overweight” rating and a $27.00 price target on the stock. KeyCorp’s price target would indicate a potential upside of 27.15% from the stock’s current price.

Several other brokerages also recently weighed in on ELAN. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Wednesday. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Piper Sandler increased their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, August 11th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a report on Wednesday. Finally, Zacks Research lowered shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus price target of $21.56.

Elanco Animal Health Stock Down 1.0%

Elanco Animal Health stock opened at $21.24 on Friday. The business’s 50-day simple moving average is $20.80 and its two-hundred day simple moving average is $16.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The company has a market cap of $10.55 billion, a PE ratio of 353.98, a PEG ratio of 2.92 and a beta of 1.71. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $23.09.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period last year, the business posted $0.13 earnings per share. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. Equities analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current year.

Institutional Trading of Elanco Animal Health

A number of hedge funds have recently added to or reduced their stakes in the company. SJS Investment Consulting Inc. grew its position in Elanco Animal Health by 2,563.5% during the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after buying an additional 1,333 shares during the period. Huntington National Bank boosted its stake in shares of Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after acquiring an additional 1,087 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its position in shares of Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after acquiring an additional 900 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after purchasing an additional 951 shares in the last quarter. Finally, Fifth Third Bancorp raised its holdings in Elanco Animal Health by 3,018.3% in the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after purchasing an additional 2,807 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.